Le Lézard
Classified in: Business
Subject: STH

Canadian Investment Regulatory Organization Trading Halt - RRL


VANCOUVER, BC, Nov. 13, 2023 /CNW/ - The following issues have been halted by CIRO

Company: Resolute Resources Ltd. 

TSX-Venture Symbol: RRL 

All Issues: Yes

Reason: Pending News

Halt Time (ET): 8:28 AM 

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) ? Halts/Resumptions


These press releases may also interest you

at 03:24
Day 1 of the London Blockchain Conference kicks off today with world-renowned marketing and business entrepreneur and professor Scott Galloway taking the stage.   Tech influencer Lilly Douse will also host this year's conference. She will bring her...

at 03:22
Sungrow, the global leading PV inverter and energy storage system provider, has forged a strategic partnership with Larsen & Toubro to supply 165MW PV inverters and 160MW/760MWh energy storage systems for AMAALA, a prestigious destination in Saudi...

at 03:14
Allied Market Research published a report, titled, "Managed Learning Service Market by Type (Sourcing External Training, L&D Administration, Supplier Management, and Others), Enterprise Size (Small & Medium Enterprises and Large Enterprises),...

at 03:03
Configit, a global leader in Configuration Lifecycle Management (CLM), today announced that Knauf Digital GmbH, a subsidiary of the Knauf Group, has implemented Configit Ace® SaaS to accelerate its Configure, Price, Quote (CPQ) process. Configit's...

at 03:01
Today sees the launch of the Leandro Herrero Institute; a membership community for leaders and professionals who want to directly benefit from Leandro's unique experience, expertise and insights. This was gained from his 25+ years pioneering a better...

at 03:00
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its...



News published on and distributed by: